E Fund Management’s Keros Therapeutics KROS Stock Holding History

E Fund Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,648	Closed	-$374K	–	343
2024 Q1	$374K	Buy	+5,648	New	+$335K	0.02%	241

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

E Fund Management's KROS Position: Q2 2024 in Review

E Fund Management sold out of Keros Therapeutics (KROS) in Q2 2024, closing a stake of 5,648 shares — an estimated $374K sold.

E Fund Management first reported a position in KROS in Q1 2024 and held it in 1 quarter. The position peaked at $374K in Q1 2024. 152 funds tracked by Wall St. Rank hold KROS as of Q2 2024.

E Fund Management reported no remaining Keros Therapeutics position as of Q2 2024 after selling out during the quarter.
E Fund Management sold 5,648 Keros Therapeutics shares in Q2 2024, an estimated $374K.
E Fund Management first reported a position in Keros Therapeutics in Q1 2024 and held it in 1 quarter.
E Fund Management's Keros Therapeutics position peaked at $374K in Q1 2024.
152 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2024.

Based on E Fund Management's 13F filing for Q2 2024, filed 12 Aug 2024.